Estimated Clinical and Economic Impact of Reducing Blood Culture Contamination

Using a Novel Initial Specimen Diversion Device? in the Emergency Department

  • Event Date:
  • Event Time: Noon Central

The impacts of blood culture contamination result in unnecessary antibiotic treatment, extended length of stay and increased hospital costs. Join Kevin Garey, professor and chair at University of Houston College of Pharmacy, as he discusses research findings recently published in the Journal of Clinical Microbiology. The researchers evaluated the potential clinical and economic benefits of an initial specimen diversion device (Steripath® ISDD®) when routinely utilized for blood culture collection in the emergency department (ED) of a quaternary care medical center. A decision analysis model was created to identify the cost-benefit of the use of the ISDD device in the ED. Antibiotic use and extended length of stay were reported based on patient admissions and probabilistic costs were determined from the published literature and the direct observation of pharmacy/microbiology staff.

Learn details of the findings, which support the routine use of Steripath during blood culture collection in the ED as a patient safety and cost-beneficial strategy to reduce the clinical and economic impact of blood culture contamination in terms of microbiology, pharmacy and wider, indirect hospital impacts.

What You Will Learn:

  • The clinical and economic impact associated with a false-positive blood culture
  • The direct and indirect costs associated with a single false-positive blood culture event
  • The expected cost savings per averted blood culture contamination event and blood culture draw (direct microbiology, pharmacy and indirect hospital costs) with the routine use of Steripath in the ED of a quaternary care medical center.

Sponsored by:

Magnolia Medical

« View All Events

Thought Leaders

Barbara DeBaun, RN, MSN, CIC
Improvement Advisor
Cynosure Health
Barbara DeBaun, RN, MSN, CIC image

Barbara DeBaun has over 35 years of experience in the field of infection prevention and quality improvement.  She is currently an Improvement Advisor for Cynosure Health where she provides vision and leadership in the development, implementation and facilitation of infection prevention and quality improvement initiatives for healthcare organizations.  Previously, she was an Improvement Advisor for BEACON, the Bay Area Patient Safety Collaborative, and was the Director of Patient Safety and Infection Control at California Pacific Medical Center in San Francisco.   She is currently adjunct faculty at Dominican University of California.  Barbara is a certified Infection Control Practitioner and holds a Bachelor’s degree in nursing from Pace University in New York and a Master of Science Degree in Nursing from San Francisco State University.

Barbara is an active member of APIC, the Association for Professionals in Infection Control and Epidemiology and recently served two years as an elected member of APIC Board of Directors. Prior to her board service, she served as APIC’s liaison to the Centers for Disease Control’s Hospital Infection Control Practices Advisory Committee (HICPAC).  Barbara has lectured nationally and internationally on a variety of patient safety and infection control topics and has published over a dozen articles and several book chapters.  In 2008, she was selected as Infection Control Today’s Educator of the Year. 

Kevin Garey, PharmD, MS, FASHP
Professor and Chair
University of Houston College of Pharmacy
Kevin Garey, PharmD, MS, FASHP image

Kevin Garey, PharmD, MS, FASHP is a Professor at the University of Houston College of Pharmacy and Chair of the Department of Pharmacy Practice and Translational Research.  He is an Adjunct Professor at the University of Texas School of Public Health and a Clinical Specialist and Researcher at Baylor St. Luke’s Medical Center, Houston, Texas.

Dr. Garey is a member of the Infectious Diseases Society of American (IDSA) Standards and Practice Guidelines Committee and is a member of the IDSA-Society of Healthcare Epidemiology of America (SHEA) practice guidelines for C. difficile infection.  He is an active member of the Society of Infectious Diseases Pharmacists (SIDP) and the American Society of Health-system Pharmacists (ASHP).

Dr. Garey has published over 175 peer-reviewed articles including identification that a delay in therapy for patients with candidemia impacts mortality and identification of a genetic risk for C. difficile infection.

On Demand Button